Minireviews
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Sep 24, 2016; 6(3): 542-547
Published online Sep 24, 2016. doi: 10.5500/wjt.v6.i3.542
Hemodynamic monitoring in heart failure and pulmonary hypertension: From analog tracings to the digital age
Ryan Davey, Amresh Raina
Ryan Davey, Amresh Raina, Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA 15212-4772, United States
Author contributions: Both authors contributed equally to this work with regards to article conception, writing and final editing of the manuscript.
Conflict-of-interest statement: Dr. Davey has no relevant financial relationships; Dr. Raina is a consultant for St. Jude’s Medical.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Amresh Raina, MD, FACC, Associate Director (Pulmonary Hypertension Program, Section of Heart Failure/Transplant/MCS and Pulmonary Hypertension), Assistant Professor of Medicine (Temple University School of Medicine), Cardiovascular Institute, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212-4772, United States. araina@wpahs.org
Telephone: +1-412-3594760 Fax: +1-412-3596544
Received: April 28, 2016
Peer-review started: April 29, 2016
First decision: June 17, 2016
Revised: July 6, 2016
Accepted: July 29, 2016
Article in press: August 1, 2016
Published online: September 24, 2016
Abstract

Hemodynamic monitoring has long formed the cornerstone of heart failure (HF) and pulmonary hypertension diagnosis and management. We review the long history of invasive hemodynamic monitors initially using pulmonary artery (PA) pressure catheters in the hospital setting, to evaluating the utility of a number of implantable devices that can allow for ambulatory determination of intracardiac pressures. Although the use of indwelling PA catheters has fallen out of favor in a number of settings, implantable devices have afforded clinicians an opportunity for objective determination of a patient’s volume status and pulmonary pressures. Some devices, such as the CardioMEMS and thoracic impedance monitors present as part of implantable cardiac defibrillators, are supported by a body of evidence which show the potential to reduce HF related morbidity and have received regulatory approval, whereas other devices have failed to show benefit and, in some cases, harm. Clearly these devices can convey a considerable amount of information and clinicians should start to familiarize themselves with their use and expect further development and refinement in the future.

Keywords: Hemodynamic monitoring, Right heart catheterization, Pulmonary hypertension, Heart failure, Left ventricular assist device, Transplant, Outcomes

Core tip: Hemodynamic monitoring forms the cornerstone of heart failure (HF) and pulmonary hypertension diagnosis and management. We review invasive hemodynamic monitors including a number of implantable devices that can allow for ambulatory determination of a variety of intracardiac pressures. These implantable devices have afforded clinicians an opportunity for objective determination of a patient’s volume status and pulmonary pressures. Devices such as the CardioMEMS and thoracic impedance monitors are supported by a body of evidence that show the potential to reduce HF related morbidity. Clinicians should start to familiarize themselves with their use and expect further development and refinement in the future.